Elucidating the cellular mechanisms of prion propagation and clearance for devising new targets for intervention in prion disease There are an increasing number of neurodegenerative disorders which result from the aggregation of misfolded proteins and which share patho-physiological mechanisms. Prion diseases are the prototypical protein misfolding diseases, and their pathogenesis is associated solely with aberrant misfolding of a single cellular protein (PrPc). Prion diseases are unique in this group as they are infectious disorders found in man and animals. Besides sporadic or genetic manifestation, they can be acquired by infection and transmitted between species, resulting in endemic or epidemic scenarios (e.g. BSE/vCJD and CWD). They can be controlled, but eradication is impossible. Therefore, it is mandatory to understand the molecular and cellular requirements for propagation and transmission of prions in order to device rational strategies for controlling these events. Advances in understanding prion patho-physiology will have major implications for other protein misfolding diseases, as it may help elucidate common cellular mechanisms. Such understanding is of fundamental scientific importance as neurodegenerative diseases represent one of the biggest health problems in our aging society, and uncovering molecular mechanisms of general validity is fundamental for the identification of new targets and development of rational therapies. The long-term goal of our group is to develop therapeutic and prophylactic anti-prion strategies. The overall objective we have is to study the cellular and molecular biology of prion infections and to use gained understanding for delineating novel targets for intervention. We have focused our attempts on two main strategies. One is the endogenous cellular clearance capacity for prions, the other one is to target the cellular isoform PrPc, which is a prerequisite for prion conversion and execution of neurodegeneration. It is our central hypothesis that it is feasible to interfere in prion propagation by increasing the cellular clearance for prions. Work in Aim 1 will substantiate our finding that prion clearance can be enhanced by compound-induced induction of autophagy, a basic cellular program for degradation and recycling. The proposed work intends to better understand the underlying molecular mechanisms and to validate the therapeutic and translational potential of this finding in vivo. Work in Aim 2 and 3 addresses cellular modifiers of prion formation. We have found that a basal level of autophagy is needed for establishing prion infection and we propose that autophagy represents the biological equivalent for the postulated disaggregase function in mammalian prion/prion-like biology. Our goal is to prove this at the cellular and molecular level. The rational for work in Aim 3 is that protein quality control mechanisms in the secretory pathway can directly influence prion conversion by determining on the quality of conversion substrates. We want to manipulate this by over-expressing folding and sorting proteins, in order to show that this represents a novel pathway counteracting prion propagation. Overall, our studies will provide mechanistic insights into basic cellular and molecular mechanisms which are relevant for neurodegenerative diseases and will result in novel targets for rational therapy against prion diseases and protein misfolding disorders.
Understanding how prions reproduce at the cellular level is necessary for developing rational strategies to fight against prion diseases. We are using existing cellular programs which we manipulate in a way that this either disfavors the formations of prions or induces their degradation. Our work provides mechanistic insights into basic mechanisms which are relevant for neurodegenerative diseases and will result in novel targets for rational therapy against prion diseases and protein misfolding disorders.
|Abdulrahman, Basant A; Abdelaziz, Dalia; Thapa, Simrika et al. (2017) The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. Sci Rep 7:17565|
|Shim, Su Yeon; Karri, Srinivasarao; Law, Sampson et al. (2016) Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells. Sci Rep 6:21658|
|Taguchi, Yuzuru; Schätzl, Hermann M (2014) Small-scale Triton X-114 Extraction of Hydrophobic Proteins. Bio Protoc 4:|
|Taguchi, Yuzuru; Schätzl, Hermann M (2014) Small-scale Subcellular Fractionation with Sucrose Step Gradient. Bio Protoc 4:|
|Kyle, Leah M; John, Theodore R; Schatzl, Hermann M et al. (2013) Introducing a rigid loop structure from deer into mouse prion protein increases its propensity for misfolding in vitro. PLoS One 8:e66715|
|Taguchi, Yuzuru; Mistica, Arla M A; Kitamoto, Tetsuyuki et al. (2013) Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. PLoS Pathog 9:e1003466|
|Taguchi, Yuzuru; Schätzl, Hermann M (2013) Identifying critical sites of PrP(c)-PrP(Sc) interaction in prion-infected cells by dominant-negative inhibition. Prion 7:452-6|
|Lisa, Silvia; Domingo, Beatriz; Martínez, Javier et al. (2012) Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms. J Biol Chem 287:36693-701|